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Vasilis Vasiliou1* and Daniel W Nebert2We live in exciting times. Mind-blowing advances in
high-throughput technology are occurring at an ever-
increasing rate. Next-generation sequencing methods
(both whole-exome and whole-genome) are generating
an explosion in the amount of new bioinformatics data.
Since mid-2010, genome-wide exome sequencing has
successfully identified the mutated gene for a number of
rare autosomal recessive and X-linked disorders. Whole-
genome sequencing of a number of different cancers, espe-
cially combined with comparison of DNA sequence from
the normal corresponding cell type in the same patient, has
revealed a number of novel variants in genes participating
in genetic networks that appear to be associated with the
tumorigenesis process. A recent achievement is the whole-
genome sequencing from patients with advanced breast
cancer, thereby leading to the identification of distinct can-
cer ‘signatures’ that may predict therapeutic outcome in
women on estrogen-lowering therapy, while preventing
others from receiving unnecessary treatment. Advances in
human genome analysis, metabolomics (using combina-
tions of ultra-high-pressure liquid chromatography, mass
spectrometry, and nuclear magnetic resonance spectros-
copy), transcriptomics, epigenetics (DNA-methylation pat-
terns, microRNA chips, histone modifications, and
chromatin remodelling) and drug discovery using high-
throughput screening—all will enhance our understanding
and elucidation of human complex diseases and should im-
prove diagnosis and treatment.
We wish to welcome you to Volume 6 of Human
Genomics with exciting news. The Human Genomics jour-
nal is now under BioMed Central as a peer-reviewed, open-
access, online journal. Human Genomics will continue to
focus on applications of genomic and epigenomic analyses
in understanding and elucidation of human complex dis-
eases as well as other multifactorial traits. This will include
diagnosis, treatment and intervention in human common
diseases—as well as better understanding of Mendelian* Correspondence: Vasilis.Vasiliou@ucdenver.edu
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Our editorial board remains virtually the same, with a few
additions coming up in the near future. All the back-
content issues (Volumes 1–5) of Human Genomics are now
freely available on the journal's website.
Human Genomics is rather unique to other journals with
its position at the interface between Big Pharma and aca-
demic research, publishing primary research and review
articles relevant to both, and arising from both industry
and academia. Areas that are covered, but are not limited
to, include the following: pharmacogenomics, genome-wide
association studies, genome-wide exome sequencing,
next-generation whole-genome sequencing, functional
genomics, translational genomics, expression profiling, epi-
genomics, proteomics, bioinformatics, animal models,
statistical genetics, genetic epidemiology, human population
genetics and comparative genomics.
We will also continue to have our highly successful
mini-reviews on (i) Gene Family Updates, (ii) Software
Reviews and (iii) Genome Databases.
Gene Family Updates are mini-reviews that examine
important human gene families and, if needed, recommend
the most appropriate gene family nomenclature—based
upon divergent evolution.
Software Reviews describe and evaluate critical
software recently available, e.g. analysis of large genome-
related datasets (genome-wide association studies, next-
generation sequencing copy-number variant patterns,
DNA-methylation examples, microRNA chip assays,
linkage analysis, gene-expression microarray and
RNA-sequencing studies, genetic variants and genomic
variability, assembly, annotation, phylogenetic analysis, gene
structure and genetic architecture).
Genome Databases represent mini-reviews describing
and/or evaluating databases, thereby providing informa-
tion regarding the human genome (DNA sequences,
microRNAs, large-effect vs. small-effect genes, genomic
variability, comparative genomics, human diseases,
pharmacogenetics, pharmacogenomics, adverse drug
reactions, individualised drug therapy, personalised
medicine, etc.).
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